Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +72

Moderna (MRNA) Stock: Rally 7.38% as $1.3B Revenue and Positive Cancer Trial Results Boost Optimism

Clinical trial results Earnings report Regulatory approval AI-generated analysis

πŸ“ˆ Moderna stock rallied 7.38% to $259.25 after reporting third-quarter revenue of $1.3 billion, a 29% increase from the prior year.

πŸ’° The company returned to profitability with $162 million in net income and $0.38 diluted EPS, reversing a loss from the previous year.

πŸš€ Management raised its 2026 annual revenue growth forecast to 15%-25%, exceeding the prior maximum guidance of 10%.

πŸ’΅ Year-end cash reserves were upgraded to a range of $8.1 billion to $8.3 billion following recent financing proceeds.

πŸ”¬ Phase 3 melanoma trial data showed intismeran combined with Keytruda reduced recurrence or death risk by 42% compared to Keytruda alone.

βœ… U.S. regulators approved Moderna's mFLUSIVA influenza vaccine for adults aged 50 and older, including accelerated approval for those 65+.

πŸ“‰ Research spending was lowered to $583 million in the quarter as the company reduced late-stage clinical development costs.

⚠️ The norovirus vaccine program missed its interim threshold for early success in Phase 3 testing.

🌍 International markets contributed $533 million in revenue, supporting the expectation of equal U.S. and international revenue shares.

Bullish Signals
  • Moderna stock jumped 7.38% to $259.25 following a strong third-quarter where revenue climbed 29% to $1.3 billion.
  • The company swung to a $162 million quarterly profit with $0.38 EPS, marking a return to profitability after a loss last year.
  • Management raised its 2026 annual revenue growth forecast to 15%-25%, significantly above the previous maximum guidance of 10%.
  • Year-end cash forecasts were increased to $8.1 billion-$8.3 billion, up from a prior projection of $4.7 billion-$5.2 billion.
  • Positive Phase 3 melanoma data showed a 42% drop in recurrence or death risk for intismeran combined with Keytruda.
  • U.S. regulators approved the mFLUSIVA influenza vaccine for adults aged 50 through 64 and granted accelerated approval for those 65 and older.
Risk Factors
  • The norovirus vaccine program missed the interim threshold for early success in Phase 3 testing.
  • Cost of sales increased 54% to $318 million due to higher vaccine volumes and manufacturing expenses, though offset by lower research spending.
Full Analysis
Moderna (MRNA) shares surged 7.38% to $259.25 following a robust third-quarter performance characterized by significant revenue growth and a return to profitability. The company reported quarterly revenue of $1.3 billion, representing a 29% year-over-year increase driven primarily by rising international vaccine sales and government agreements. This financial strength allowed Moderna to swing from a loss in the prior year to a net income of $162 million, with diluted earnings per share reaching $0.38. Beyond immediate quarterly results, Moderna has substantially upgraded its long-term outlook, raising its annual revenue growth forecast for 2026 to a range of 15% to 25%, surpassing previous conservative estimates. The company also increased its year-end cash balance projection to between $8.1 billion and $8.3 billion, bolstered by recent financing activities. Management indicated that while cost of sales rose due to higher volumes, lower research spending helped offset these increases, resulting in a healthier bottom line. Clinically, Moderna delivered mixed but strategically significant news with positive Phase 3 data for its melanoma therapy intismeran combined with Merck's Keytruda, showing a 42% reduction in recurrence or death risk. While the norovirus vaccine program missed interim success thresholds, the company secured regulatory approval for its mFLUSIVA influenza vaccine and expects pivotal results from its propionic acidemia program before the end of 2026. Strategically, Moderna is positioning itself for a diversified revenue stream with international markets expected to contribute roughly equal shares to U.S. sales in the coming years. The company maintained its administrative expense projection while reducing full-year research spending forecasts from $2.9 billion to approximately $2.7 billion. These operational adjustments and strong cash reserves provide a solid foundation for future development and potential commercial launches of new therapies.